Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR ...Middle East

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR. ASC36_35 FDC demonstrated approximately 51% greater relative body weight...

Hence then, the article about ascletis submits two ind applications to the u s fda for the treatment of obesity asc36 once monthly injection a peptide amylin receptor agonist and asc36 35 fdc once monthly injection a co formulation of asc36 plus peptide glp 1r gipr was published today ( Monday 06/07/2026 - 04:15 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR )

Also on site :

• US Congressman denies existence of Palestinians in interview
• Mumbai rain havoc: Schools and colleges shut on Monday; flights hit, roads flooded
• The CEO who vowed to ‘fire anyone who doesn’t use AI’ admits that the technology can’t replace her executive assistant as the role evolves